The International Myeloma Working Group (IMWG) recommends that an average of 8 × 106 CD34+ cells/kg should be given if mobilized, and that the minimum administration target should be 4 × 106 CD34+ cells/kg progenitor cells for auto-HCT eligible MM patients [9]. Here, CD34 is linked to Miyoshi myopathy.